Toggle light / dark theme

From banking to communication our modern, daily lives are driven by data with ongoing concerns over privacy. Now, a new EPFL paper published in Nature Computational Science argues that many promises made around privacy-preserving mechanisms will never be fulfilled and that we need to accept these inherent limits and not chase the impossible.

Data-driven innovation in the form of personalized medicine, better public services or, for example, greener and more efficient industrial production promises to bring enormous benefits for people and our planet and widespread access to data is considered essential to drive this future. Yet, aggressive data collection and analysis practices raise the alarm over societal values and fundamental rights.

As a result, how to widen access to data while safeguarding the confidentiality of sensitive, has become one of the most prevalent challenges in unleashing the potential of data-driven technologies and a new paper from EPFL’s Security and Privacy Engineering Lab (SPRING) in the School of Comupter and Communication Sciences argues that the promise that any is solvable under both good utility and privacy is akin to chasing rainbows.

While Taiwan still allows Russia and Belarus to purchase CPUs from businesses within the East Asian country, there are some big caveats: their clock frequencies cannot exceed 25 MHz, and performance is limited to under 5 GFLOPS.

DigiTimes reports that Taiwan’s Ministry of Economic Affairs (MOEA) published a list this week of strategic high-tech commodities banned from exportation to Russia and Belarus. The latter country is included as MOEA believes it could help Russia import such goods.

Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL).

Updated findings from the UNITY-CLL clinical trial continued to show a possible increased risk of death in patients receiving Ukoniq. As a result, we determined the risks of treatment with Ukoniq outweigh its benefits. Based upon this determination, the drug’s manufacturer, TG Therapeutics, announced it was voluntarily withdrawing Ukoniq from the market for the approved uses in MZL and FL.

Health care professionals should stop prescribing Ukoniq and switch patients to alternative treatments. Inform patients currently taking Ukoniq of the increased risk of death seen in the clinical trial and advise them to stop taking the medicine. In limited circumstances in which a patient may be receiving benefit from Ukoniq, TG Therapeutics plans to make it available under expanded access.

Using the patient’s own cellsAn American biotech company has just announced that they have successfully transplanted a 3D printed human ear into a patient, initially reported by The New York Times. The company, Queens-based 3DBio Therapeutics, printed the ear using the patient’s own cells.


In what has been described as a world first, a U.S. company has created and transplanted a 3D-printed ear made of the patient’s own cells.

DeLorean released images and information on its upcoming 2024 electric car.

DeLorean is unapologetically human. A New Energy mobility brand.

We have a clear vision of our future, knowing it does not represent today. The DMC-12 was never meant to be a static interpretation of the brand, the brand would constantly evolve. Our icons are reimagined. DMC is and always was in constant evolution. An Icon is validated over time but to constantly reimagine mobility allows new icons to come into existence.